The NBA Hall of Famer joined forces with the telehealth platform to restart his weight loss journey and raise awareness about taking branded GLP-1s.

Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo ...

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed that ...

Shares of Hims & Hers Health skyrocketed to 40% in the premarket following the telehealth company’s partnership announcement ...

WeightWatchers (NASDAQ: WW) ("WeightWatchers," "WW," or the "Company"), the global leader in science-backed weight management, today announced a pharmacy ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

WeightWatchers (NASDAQ: WW) ("WeightWatchers,” "WW,” or the "Company”), the global leader in science-backed weight management, today announced a pharmacy integration with Eli Lilly and Company's ...

On Friday, Mad Money host Jim Cramer took a close look at what he called one of the most important stretches of the earnings ...

Eli Lilly, the drugmaker with two weight-loss bestsellers, just got its first dose of healthy skeptism during a time when the ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...